 Zynerba Pharmaceuticals NASDAQ:ZYNE Inc has reported financial results for the second quarter ended June 30, 2022, and provided an overview of its recent operational highlights and a pipeline update on its Zygel cannabidiol CBD skin gel. During the second quarter, we were pleased to announce positive topline results from our phase 2 trial of Zygel in patients with 22q, said Armando Anido, chairman and chief executive officer of Zynerba in a statement. 